More Videos
SPECIAL REPORT
MOST SHARED
- Jobless Claims Post Another Drop as Picture Improves
- Obama Plans Jobs Summit But Not Second Stimulus
- Meet The Leaders of the New Retail Revolution
- Wal-Mart Holiday Forecast Light, Profit Beats
- A Public Hearing That Isn't Public
- "Friending" Big Pharma
- Obama Most Powerful Person in World: Forbes
- 30 Year Mortgage Rate Falls Again; Lowest In Five Weeks
- Activision Says 'Call of Duty' Sets Launch Record
- Big Bounce Coming — Play These 6 Stocks: Chief Investor
- Wal-Mart Looks Even Better Next Quarter: Strategist
- Fourteen Stocks that Could Gain from Dollar's Decline
- Busch: Another Obama Opportunity
- Light the Lights! Buffett and Gates Prepare to Answer Students' Questions at Columbia
- Farrell: Retailers?
- A Public Hearing That Isn't Public
- Boise State's Brilliant Stock Plan
- Apple's Global Retail Invasion
- US Debating What to Do With Billions of TARP Money Left
- For Video Game Makers, Stakes Are High for Holidays
- In Charity Tax Filing, a Real Glimpse of Goldman Sachs
- Obama Begins Asia Trip, Burdened by Jobs, Economy
- FHA Reserves Fall Below Required Level: HUD Chief
- 30-Year Mortgage Rate Falls Again; Lowest in Five Weeks
- Ford, Hyundai, Audi Gaining Consumer Interest
- US Mortgage Refinancing Up; Buying Demand Sinks
- Intel Agrees to Pay AMD $1.25 Billion to Settle Disputes
RSS FEED
Pharma's Market
Text Size 
 |
CNBC.com |
But what about the work-a-day primary care physicians who actually write the overwhelming majority (an estimated 75 percent) of the scripts for cholesterol-lowering drugs?
Well, Deutsche Bank this morning is out with the results of a survey it did involving 101 PCPs. And it doesn't look good for MRK [MRK
Loading...
()
] and SGP [SGP
Loading...
()
]. AstraZeneca [AZN
Loading...
()
] , though, may come through smelling like a rose.
DB's big pharma analyst Barbara Ryan writes in the research note to clients: "These datapoints suggest both additional abrupt and sustained declines for Vytorin and Zetia and increased utilization of other statins, especially Crestor." AZN makes Crestor and last week it ended one study early because the drug worked so well.
The Detusche poll shows that on average Vytorin scripts will fall from 16 percent market share to nine percent. And Zetia's piece will drop from nine-and-a-half percent to six percent. Overall, Ryan expects a total Vytorin and Zetia "unit decline" of 32 percent this year.
The survey says doctors are or will be putting fewer patients on Vytorin and Zetia and switching some of their patients off of those drugs.
They'll be moved onto Pfizer's [PFE
Loading...
()
] Lipitor and generic Zocor, but Ryan believes: "the primary beneficiary in terms of share gains appears to be Crestor."
Deutsche Bank makes a market in SGP & MRK and owns at least one percent of the shares of both.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes